purine nucleotide interconversion enzymes Inhibitors
2 drugsAbout purine nucleotide interconversion enzymes
Purine nucleotide interconversion enzymes are essential for synthesizing and maintaining cellular purine nucleotide pools, the building blocks of DNA and RNA. They catalyze the interconversion of different purine nucleotides, ensuring the correct balance for various cellular processes.
Targeting these enzymes is a viable strategy in oncology due to the high demand for nucleotide synthesis in rapidly dividing cancer cells. Disrupting purine nucleotide metabolism can selectively inhibit cancer cell growth, though no genetic evidence directly links these enzymes to specific diseases.
Two FDA-approved drugs, PURIXAN and PURINETHOL, target purine nucleotide interconversion enzymes in oncology. Both drugs are small molecules, developed by NOVA LABS LTD and STASON PHARMS respectively.
Top purine nucleotide interconversion enzymes Drugs
The competitive landscape consists of two companies, NOVA LABS LTD and STASON PHARMS.
Low market concentration suggests relatively low barriers to entry for new competitors.
purine nucleotide interconversion enzymes Drug Modality Landscape
Modalities
Routes of Administration
purine nucleotide interconversion enzymes is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs represents a whitespace opportunity.
purine nucleotide interconversion enzymes Clinical Trials 87 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on purine nucleotide interconversion enzymes. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 5 | 2 | 9 | 71% |
| Phase 2 | 44 | 12 | 7 | 25 | 63% |
| Phase 3 | 23 | 10 | 0 | 13 | 100% |
| Phase 4 | 4 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
purine nucleotide interconversion enzymes Drug Approval Timeline (1953 - 2014)
The approval timeline spans 62 years, from PURINETHOL (1953) to PURIXAN (2014).
The long approval gap indicates potential saturation or challenges in developing new drugs in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 39 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on purine nucleotide interconversion enzymes. A trial counts if an approved drug acting on purine nucleotide interconversion enzymes is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.